Oilfield services company Core Laboratories (NYSE:CLB) announced in Q1 CY2026, but sales fell by 1.4% year on year to $121.8 million. Its GAAP loss of $0.02 per share was significantly below analysts’ consensus estimates.

Q1 2026 Management view "The military conflict in the Middle East introduced geopolitical uncertainties that created meaningful disruptions across the Middle East countries in which we operate" (Chairman of the Board,

Core Lab Earnings: Solid Quarter in Line With Expectations Wide-moat Core Laboratories posted third-quarter results mostly in line with our estimates. Revenue of $134 million was up 3% sequentially and 7% year over year, while operating income of $20 million was up 11% sequentially and 14% year over year. Still, we are lowering our fair value estimate to $21 per share from $22 due to near-term ...

(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards. (2) Three months ended September 30, 2023 ...

due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions ...